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Abstract 
Introduction 
 For some adults with asthma, symptom relief is inadequate 
when receiving treatment with an ICS and a LABA.  Besides 
increasing the amount of steroid to a maximum dose, which 
comes with increased side effects, there has been no other 
alternative. 
 Recently it has come into question whether or not the addition 
of anticholinergic agents such as tiotropium would be useful 
addition to asthma patients who remain symptomatic despite 
max therapy. 
Research Question 
Literature Review 
Applicability to Clinical 
Practice 
thanks . . .  
Discussion 
 
 
 
 Many patients with asthma have poorly controlled disease 
despite the use of both an inhaled corticosteroid (ICS) and a long 
acting beta agonist (LABA).   
 The review explored several studies that compared the addition 
of tiotropium to patients with uncontrolled asthma currently 
using both a ICA and a LABA to determine if further symptom 
reduction is obtained along with reduction of exacerbations 
 It was found that patients with poorly controlled asthma will 
benefit from the addition of tiotropium to the current medication 
regimen of an ICS and a LABA.  Tiotropium offers providers an 
additional disease controlling option in cases where treatment is 
already limited. 
 In adult patients with uncontrolled asthma using maximum 
doses of both ICS and a LABA, will the addition of tiotropium 
improve lung function and reduce the number of asthma related 
exacerbations? 
 Is tiotropium safe and efficacious? 
 Is tiotropium cost effective compared to other therapeutics?  
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Statement of the Problem 
 Asthma has become a worldwide epidemic.  Further research ad 
therapy needs to be initiated to reduce morbidity and mortality 
in those patients already on maximum recommended drug 
regimen. 
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 Tiotropium may have a place in clinical practice for 
those patients with uncontrolled asthma already on 
max therapy with an ICS and a LABA, as the small 
improvements in lung function will benefit this group 
in the long run. 
 However, tiotropium most likely does not have a place 
in clinical practice for those patients who have 
symptom control. 
 The search of Literature identified the main points: 
 Kerstjens (2012) found that at 24 weeks the peak FEV₁ 
with the addition of tiotropium, increased slightly 
(P=0.01), and the time to first exacerbation was increased 
by 56 days (P=0.03) 
 Peters (2010) found that those patients receiving 
tiotropium had a morning PEF that was 25.8L/min higher 
than those patients receiving a double dose of 
glucocorticoid (P=<0.001).   
 Tang (2013) found improvements in trough FEV₁ at 4 
weeks (P<0.0001), 24 weeks (P<0.0001) and 48 weeks 
(P<0.0001) in the tiotropium group versus placebo. 
 In a systematic review by Kesten (2009), tiotropium 
showed no increased risk for cardiac or vascular events 
when compared to placebo. 
 A cost analysis by Hoogendoorn (2012), found tiotropium 
was more expensive when compared to salmeterol, but 
had lower overall costs when exacerbations were taken 
into effect. 
 Dalal (2010) found that unadjusted mean costs of 
treatment with fluticasone/salmeterol ($2018) was lower 
when compared with tiotropium ($2453). 
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Journal of Medicine, 367, p. 1204 
 Ultimately all of the studies showed modest improvement in 
lung function and number of days between severe 
exacerbations with the addition of tiotropium. 
Discussion 
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